Opinion|Videos|October 13, 2023

Updates in the Management of Lower-Risk MDS

Author(s)Amer Zeidan, MBBS

Amer Zeidan, MBBS, MHS, reviews recent luspatercept and imetelstat data from the COMMANDS and IMerge clinical trials in lower-risk myelodysplastic syndrome.

Episodes in this series

Elias Jabbour, MD, an expert on myelodysplastic syndrome

EP. 1 Overview of Myelodysplastic Syndrome

Elias Jabbour, MD, an expert on myelodysplastic syndrome

EP. 2 Clinical Insights on Treating Myelodysplastic Syndrome

Abdulraheem Yacoub, MD, an expert on myelodysplastic syndrome

EP. 3 IMerge Trial: Key Efficacy Outcomes

Abdulraheem Yacoub, MD, an expert on myelodysplastic syndrome

EP. 4 Data Updates From the IMerge Trial

Eytan M. Stein, MD, an expert on myelodysplastic syndrome

EP. 5 Follow-Up Efficacy Data of Imetelstat in Lower-Risk MDS

Eytan M. Stein, MD, an expert on myelodysplastic syndrome

EP. 6 Evolving Treatment Landscape in Lower-Risk MDS

EP. 7 Safety Outcomes for Imetelstat in Lower-Risk MDS

Amer Zeidan, MBBS, MHS, an expert on myelodysplastic syndrome

EP. 8 Updates in the Management of Lower-Risk MDS

Amer Zeidan, MBBS, MHS, an expert on myelodysplastic syndrome

EP. 9 Recent Updates in Lower-Risk MDS

Yazan Madanat, MD, an expert on myelodysplastic syndromes

EP. 10 Updates in Lower-Risk MDS: Imetelstat

Yazan Madanat, MD, an expert on MDS

EP. 11 Key Updates in Lower-Risk MDS

Newsletter

Stay up to date on practice-changing data in community practice.

Related to this article

Behind the FDA Approval: Rusfertide Redefines the Polycythemia Vera Paradigm

October 4th, 2026

Behind the FDA Approval: Rusfertide Redefines the Polycythemia Vera Paradigm

Andrew T. Kuykendall, MD, explains the significance of the FDA approval of rusfertide for polycythemia vera.

Insurance Hurdles and High Costs Impede Access to Oral Blood Cancer Drugs

October 2nd, 2026

Insurance Hurdles and High Costs Impede Access to Oral Blood Cancer Drugs

Insurance hurdles and steep out-of-pocket costs often delay or prevent patients from filling specialty oral blood cancer drugs, even after eventual approvals.

Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

Behind the FDA Approval: Rusfertide Redefines the Polycythemia Vera Paradigm

FDA Grants Fast Track Designation to TRE-515 for KRAS G12C NSCLC

Pirtobrutinib Gains FDA Approval for Frontline CLL/SLL in Select Patients

Extended Survival Raises New Questions on Imaging and Treatment Intensification in ROS1+ NSCLC

Ubamatamab Shows Durable Responses in Low-Grade Serous Ovarian Cancer